Lion's Mane (Hericium erinaceus) is a shaggy, white culinary mushroom that has become one of the most talked-about "brain mushrooms" on the market, built almost entirely on one mechanism: compounds in the mushroom appear to stimulate nerve growth factor (NGF), a protein that supports the growth and survival of neurons. That mechanism is real and well-documented — in cell cultures and in animals. In humans, the picture is thinner and more mixed than the marketing suggests. A handful of small randomized controlled trials, ranging from 18 to 41 participants, have tested Lion's Mane against placebo for cognition, mood and stress. Some found statistically significant effects on specific measures; others found nothing on their primary composites, and one reported limited negative findings alongside its positive one. Nobody has yet run a large, long trial in a general adult population and shown a clear, repeatable cognitive benefit. This is an honest look at what the NGF story actually rests on, what the human trials say, and why Lion's Mane isn't in Proco's range today.
Evidence reviewed: September 2026.
What Lion's Mane is, and the mechanism behind the hype
Lion's Mane has a long history as a culinary and traditional-medicine mushroom in China and Japan (known there as Yamabushitake), but its modern nootropic reputation traces back to a specific discovery: two families of compounds unique to the mushroom — hericenones, found in the fruiting body, and erinacines, found in the mycelium — were shown in laboratory and animal research to stimulate NGF biosynthesis.6 NGF is a protein your body already produces; it supports the growth, maintenance and survival of certain neurons, and reduced NGF signaling has been studied as one factor in age-related cognitive decline. The logic of the supplement case is straightforward: if a compound can boost NGF production, and NGF supports neuron health, then a mushroom extract might support brain function over time.
That logic is reasonable, but it's also exactly where most of the coverage stops — at the mechanism, not the outcome. The NGF-stimulating effect has been demonstrated in cell culture (human astrocytoma cells) and in rodent studies, where erinacine-treated animals showed increased NGF mRNA expression in brain tissue.6 Nobody has directly measured whether oral Lion's Mane raises NGF levels in the human brain — that's not something you can currently test non-invasively and ethically in living people. What human trials can measure is downstream: does taking Lion's Mane actually change cognitive test scores, mood, or self-reported stress? That's a different, and much harder, question — and it's the one that matters for whether the ingredient does anything for you. It's the same gap between mechanism and outcome that we walk through for the whole category in why we don't sell brain blends.
What the human trials actually show
As of this review, four small randomized, placebo-controlled human trials and one broader systematic review make up the core evidence base. Here's each one, plainly.
| Trial | Population / n | Dose & duration | Result |
|---|---|---|---|
| Mori et al., 20091 | Adults 50–80 with mild cognitive impairment, n=30 (15 per arm) | 3g/day fruiting-body powder (four 250mg tablets, three times daily), 16 weeks | Scores on a Hasegawa-based cognitive scale rose significantly at weeks 8, 12 and 16 vs. placebo — then fell significantly within 4 weeks of stopping |
| Saitsu et al., 20192 | Healthy adults, n=31 | Fruiting-body supplement; dose not stated in the published abstract, 12 weeks | Significant improvement on 1 of 3 cognitive tests (MMSE); the Benton visual retention and verbal paired-associate tests showed no significant change |
| Docherty et al., 20233 (pilot study) | Healthy adults 18–45, n=41 | 1.8g/day, single dose + 28 days | Faster Stroop task performance at 60 min post-dose (p=0.005); a non-significant trend toward lower stress at 28 days (p=0.051); the authors report "null and limited negative findings" alongside these |
| Surendran et al., 20254 | Healthy adults 18–35, n=18 | Single 3g dose of a 10:1 fruiting-body extract (crossover), tested at 90 min | No significant effect on composite measures of global cognition or mood; an isolated improvement on one psychomotor (pegboard) test |
Across four trials and 120 total participants, the pattern isn't "Lion's Mane works" or "Lion's Mane doesn't work" — it's one or two positive measures per study, embedded in a larger set of null results, in different populations, at different doses, for different durations.
A 2025 systematic review gathered this evidence together — five randomized controlled trials, three pilot clinical trials, 15 laboratory studies, a cohort study, a case report and a computer analysis.5 On cognition, the figure most often quoted from it is a weighted mean increase of 1.17 MMSE points in the intervention group — and it is worth being precise that this came from one RCT and one pilot trial, not from pooling all eight clinical studies. The review also reports that some trials measured reduced anxiety, depressive symptoms and sleep disturbance, alongside preclinical evidence of increased pro-BDNF and BDNF and hippocampal neurogenesis in animals, and separate in-vitro work on cancer cell lines and gut microbiota that has nothing to do with the cognition question.
One thing we got wrong before and want to correct openly: that review's own discussion is more confident than we previously described, stating that the mushroom "is effective in neuroprotection, enhancing cognitive function, preventing and alleviating cancer, promoting gut health, and improving symptoms of anxiety and depression." We think that language runs well ahead of four small human trials and a body of cell and animal work, and readers deserve to know that the caution in this article is ours rather than the review's. The review does note that side effects are inconsistently reported across the underlying studies — a limitation in the evidence base itself, not just a safety footnote.
The Mori 2009 result is worth sitting with a moment longer, because it's the most-cited trial and also the most instructive about what this evidence does and doesn't show. Thirty people with mild cognitive impairment, fifteen per arm. Cognitive scores improved steadily over 16 weeks of continuous use — then dropped significantly within a month of stopping. That pattern is more consistent with a temporary, use-dependent effect than a lasting structural change to the brain, and it means any real benefit here would likely require ongoing, indefinite use rather than a short course. It also, notably, was run in a clinical population, not the healthy adults most Lion's Mane is sold to.
Why the sample sizes matter
Trials this small — 18, 30, 31, 41 participants — aren't automatically wrong, but they're statistically fragile. A single outlier participant, a slightly different test battery, or a marginally different dose can flip a result from significant to null, or vice versa. Two of the four describe themselves as pilot or acute proof-of-concept studies. That's plausibly part of why these four trials, testing broadly similar things, land on different specific measures being the ones that improved. It's also why the difference between a real effect and an expectancy effect is so hard to separate at this scale — something we go into in what the placebo effect in supplements actually means. None of this means Lion's Mane doesn't do anything — it means the evidence isn't yet at the size and consistency where you can say with confidence what it reliably does, for whom, at what dose.
Safety
Across the trials and case reports reviewed, Lion's Mane has generally been well-tolerated, with the most commonly reported issues being mild gastrointestinal discomfort, nausea, headache or skin rash; the review notes that side effects are commonly unreported in the underlying studies, which limits how much reassurance that record can offer.5 Mori's trial reported no adverse effects on laboratory tests. Long-term safety data beyond the duration of these short trials (up to 16 weeks) doesn't yet exist. As with any mushroom-derived supplement, anyone with a known mushroom or fungal allergy should avoid it.
Where this leaves Lion's Mane at Proco
To be consistent about our own standard: Proco selects products on category fit plus basic safety, and we aren't going to pretend we run a formal evidence-depth gate that every current ingredient has cleared. Lion's Mane clearly fits the category, aimed squarely at cognitive and nervous-system support, and on those grounds it's a legitimate candidate for future consideration. What's kept it out so far is simpler and more practical: the human outcome data — as opposed to the NGF mechanism — is four small trials, with inconsistent results even within single studies, and no replication of any single finding by an independent research group. We'd want to see one well-powered trial reproduce a specific, meaningful effect before putting our name on it.
It would be easy to imply our current formula is held to a higher bar than that, and it wouldn't be true. Cognitive Support's Bacopa monnieri does have the deepest trial record of anything in the formula — though as our Bacopa write-up explains, that evidence comes from 12-week trials at 300–450mg a day of the extract alone, which is more than Cognitive Support's entire 255mg blend of eight ingredients. Alpha GPC's acute human evidence is a single crossover trial in 20 resistance-trained men. Neither ingredient's dose in our product is disclosed, for reasons we set out in Inside Cognitive Support — and if you want the general skill of reading these labels, our guide to proprietary blends and underdosing covers it. For now, on Lion's Mane, the honest answer is: promising mechanism, real but preliminary human signal, not yet enough to put our name on it. Two other ingredients sit in the same waiting room, for similar reasons — see NAC.
Bottom line
Lion's Mane has the most scientifically interesting mechanism of any ingredient we've reviewed that isn't currently in our range — a genuinely novel, cell-and-animal-confirmed pathway for supporting nerve growth. But mechanism isn't outcome, and the human trial record is still four small studies deep, with results that shift depending on which test you look at, and with one widely quoted pooled figure resting on just two studies. If you're already taking Lion's Mane and it seems to be working for you, that's a reasonable, low-risk thing to continue — the safety profile, as far as the short trials go, is good. If you're deciding whether to start, go in with accurate expectations: this is a promising, early-stage ingredient, not a settled one, and the case for it today rests more on mechanism than on consistent human outcome data. If brain fog rather than performance is the actual complaint, our brain fog write-up is a better place to start.
This article is for informational purposes only and has not been evaluated by the FDA. It is not intended to diagnose, treat, cure, or prevent any disease. Speak with a healthcare provider before starting any new supplement, especially if you take medication or have an existing health condition.
References
- Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T. "Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial." Phytotherapy Research, 2009;23(3):367-372. pubmed.ncbi.nlm.nih.gov
- Saitsu Y, Nishide A, Kikushima K, Shimizu K, Ohnuki K. "Improvement of cognitive functions by oral intake of Hericium erinaceus." Biomedical Research, 2019;40(4):125-131. pubmed.ncbi.nlm.nih.gov
- Docherty S, Doughty FL, Smith EF. "The Acute and Chronic Effects of Lion's Mane Mushroom Supplementation on Cognitive Function, Stress and Mood in Young Adults: A Double-Blind, Parallel Groups, Pilot Study." Nutrients, 2023;15(22):4842. pmc.ncbi.nlm.nih.gov
- Surendran G, Saye J, Binti Mohd Jalil S, et al. "Acute effects of a standardised extract of Hericium erinaceus (Lion's Mane mushroom) on cognition and mood in healthy younger adults: a double-blind randomised placebo-controlled study." Frontiers in Nutrition, 2025;12:1405796. frontiersin.org
- Menon A, Jalal A, Arshad Z, Nawaz FA, Kashyap R. "Benefits, side effects, and uses of Hericium erinaceus as a supplement: a systematic review." Frontiers in Nutrition, 2025;12:1641246. pubmed.ncbi.nlm.nih.gov
- Kawagishi H, Zhuang C. "Hericenones and erinacines: stimulators of nerve growth factor (NGF) biosynthesis in Hericium erinaceus." International Journal of Medicinal Mushrooms. tandfonline.com
See what's currently in Cognitive Support today — ten named actives, two of them individually dosed and eight inside a 255mg blend.